1. Search Result
Search Result
Results for "

Noncovalent

" in MedChemExpress (MCE) Product Catalog:

242

Inhibitors & Agonists

4

Screening Libraries

6

Fluorescent Dye

23

Biochemical Assay Reagents

34

Peptides

1

Inhibitory Antibodies

14

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3152
    Streptavidin
    5 Publications Verification

    Biochemical Assay Reagents Others
    Streptavidin is a ~60 kDa homotetramer. Streptavidin binds four molecules of biotin with the highest affinity. The binding affinity of biotin to streptavidin is one of the highest reported for a non-covalent interaction to date, with a KD ~0.01 pM . Streptavidin has an immunosuppressive role .
    This product is a Streptavidin protein recombinantly expressed in an E. coli expression system.
    Streptavidin
  • HY-135146
    GSK-3484862
    20+ Cited Publications

    DNA Methyltransferase Cancer
    GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity .
    GSK-3484862
  • HY-114299
    Salcaprozate sodium
    4 Publications Verification

    SNAC

    Biochemical Assay Reagents Others
    Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .
    Salcaprozate sodium
  • HY-139664
    GSK-3685032
    10+ Cited Publications

    DNA Methyltransferase Cancer
    GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition .
    GSK-3685032
  • HY-152857

    LY3473329

    LDLR Cardiovascular Disease
    Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .
    Muvalaplin
  • HY-143216
    Ensitrelvir
    10+ Cited Publications

    S-217622

    SARS-CoV Virus Protease Infection
    Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) .
    Ensitrelvir
  • HY-112215
    Nemtabrutinib
    4 Publications Verification

    ARQ-531; MK-1026

    Btk Inflammation/Immunology Cancer
    Nemtabrutinib (ARQ 531) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
    Nemtabrutinib
  • HY-117043
    GRL0617
    10+ Cited Publications

    Deubiquitinase SARS-CoV Infection
    GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome .
    GRL0617
  • HY-W095670

    Drug Intermediate Others
    2,4,7-Trichloro-8-fluoropyridopyrimidine is a pyridopyrimidine synthetic intermediate of MRTX1133 (HY-134813), which can be used for the synthesis of non-covalent KRAS G12D inhibitors .
    2,4,7-Trichloro-8-fluoropyrido[4,3-d]pyrimidine
  • HY-109198

    ME-401; PWT-143

    PI3K Akt Cancer
    Zandelisib (ME-401) is a selective, orally active, non-covalent inhibitor of PI3Kδ. Zandelisib can sustainably inhibit AKT phosphorylation and downstream signaling pathways. Zandelisib can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma .
    Zandelisib
  • HY-29035

    Collagen Others
    Dopamine acrylamide, a polyphenol derivative, can cross-link collagen mainly via noncovalent bonding under acidic-non-oxidized conditions .
    Dopamine acrylamide
  • HY-19750
    TBA-7371
    1 Publications Verification

    Bacterial Infection
    TBA-7371 is an orally active and non-covalent inhibitor of Decaprenylphosphoryl-β-D-ribose oxidase (DprE1) of Mycobacterium tuberculosis (MIC=0.64 μg/mL). TBA-7371 can block the synthesis of arabinose in the bacterial cell wall, resulting in cell wall structural defects, thereby exerting an anti-tuberculosis effect. TBA-7371 can be used in the research of anti-tuberculosis drugs and has a synergistic bactericidal effect with Bedaquiline (HY-14881) and other drugs .
    TBA-7371
  • HY-143216A
    Ensitrelvir fumarate
    10+ Cited Publications

    S-217622 fumarate

    SARS-CoV Virus Protease Infection
    Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) .
    Ensitrelvir fumarate
  • HY-136430

    JGK037

    EGFR Cancer
    JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively .
    JCN037
  • HY-139535
    Luxeptinib
    1 Publications Verification

    CG-806

    FLT3 Btk Apoptosis Cancer
    Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .
    Luxeptinib
  • HY-109078
    Vecabrutinib
    2 Publications Verification

    SNS-062

    Btk Itk Cancer
    Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC50 of 24 nM for ITK .
    Vecabrutinib
  • HY-136298A

    SARS-CoV Infection
    X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM .
    X77
  • HY-141514
    MSA-2 dimer
    1 Publications Verification

    STING Inflammation/Immunology Cancer
    MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (Kd=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide .
    MSA-2 dimer
  • HY-156820

    Epigenetic Reader Domain Cancer
    HLDA-221 is a non-covalent regulated induced proximity targeting chimeras (RIPTAC). The binding of HLDA-221 to BRD4-BD1 is significantly increased after pre-incubation with FKBP. HLDA-221 can be used in cancer research .
    HLDA-221
  • HY-160167

    DZD8586

    Src Btk Inflammation/Immunology Cancer
    Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .
    Birelentinib
  • HY-133130
    JNJ-42226314
    1 Publications Verification

    MAGL Neurological Disease
    JNJ-42226314, a chemical probe, is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-15256

    BI 201335

    HCV Protease Infection
    Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .
    Faldaprevir
  • HY-P2265A

    SOS1 Ras Cancer
    SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .
    SAH-SOS1A TFA
  • HY-10243

    MK-7009

    HCV HCV Protease Infection
    Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
    Vaniprevir
  • HY-19415

    Phospholipase Metabolic Disease
    SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM .
    SB-435495
  • HY-103462

    FAAH Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
    TC-F2
  • HY-153178

    E1/E2/E3 Enzyme Others
    HECT E3-IN-1 (compound 3) is a HECT E3 ligase inhibitor. HECT E3-IN-1 (compound 3) disrupts Ub binding to the noncovalent Ub-binding site of Nedd4-1 .
    HECT E3-IN-1
  • HY-101790A

    NEDD8-activating Enzyme Cancer
    ZM223 hydrochloride is an orally active, potent non-covalent NEDD8 activating enzyme (NAE) inhibitor with excellent anticancer activity .
    ZM223 hydrochloride
  • HY-136259
    ML188
    5 Publications Verification

    SARS-CoV Virus Protease Infection
    ML188, a first in class probe, is a selective non-covalent SARS-CoV 3CLpro inhibitor with an IC50 of 1.5 μM. Antiviral activity .
    ML188
  • HY-150308

    PPAR Cancer
    SR10221, a noncovalent inverse agonist of PPARγ, represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines .
    SR10221
  • HY-131328A

    (R)-LOXO-305

    Btk Others
    (R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations .
    (R)-Pirtobrutinib
  • HY-126278

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    Z1609609733 (Compound 18) is a non-covalent 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 1.46 μM. Z1609609733 significantly inhibits serine synthesis and cancer metabolism with complete abrogation of cell proliferation .
    Z1609609733
  • HY-136531

    Btk Apoptosis Cancer
    XMU-MP-3 is a potent non-covalent BTK inhibitor with IC50s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation in the presence of 10 μM ATP, respectively. XMU-MP-3 also induces apoptosis .
    XMU-MP-3
  • HY-161079

    Parasite Infection
    TDI-8304, a macrocyclic peptide, is a potent, species selective, and noncovalent Plasmodium falciparum (Pf20S) inhibitor. TDI-8304 shows highly selective for Pf20S over human proteasomes .
    TDI-8304
  • HY-175596

    ClpP Bacterial Infection
    ACP1-01 is a bacterial ClpP activator with EC50s of 3.4 and 2.6  μM for Neisseria meningitides ClpP (NmClpP) and Escherichia coli ClpP (EcClpP). ACP1-01 noncovalently binds to ClpP C sites and activates the protease. ACP1-01 has antibacterial activity. ACP1-01 can be used for bacterial infections research .
    ACP1-01
  • HY-19415B

    Phospholipase Metabolic Disease
    SB-435495 ditartrate is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM .
    SB-435495 ditartrate
  • HY-174914

    Biochemical Assay Reagents Others
    Biotin-PEG4-mal is a PEG derivative composed of Biotin, 4 PEG units and Maleimide. Biotin can form a stable non-covalent bond with streptavidin.
    Biotin-PEG4-mal
  • HY-174938

    Biochemical Assay Reagents Others
    Biotin-PEG3-Iodoacetamide is a PEG derivative composed of Biotin, 3 PEG units, and Iodoacetamide. Biotin can form a stable non-covalent bond with streptavidin.
    Biotin-PEG3-Iodoacetamide
  • HY-P2265

    SOS1 Ras Cancer
    SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .
    SAH-SOS1A
  • HY-P2261
    STAD 2
    1 Publications Verification

    PKA Infection
    STAD 2 is a potent and selective disruptor of PKA-RII, with a Kd of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism .
    STAD 2
  • HY-134184

    AUTACs Autophagy Inflammation/Immunology Cancer
    AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .
    AUTAC2
  • HY-168432

    Phytohormone Others
    KK181N1 is a potent inhibitor of karrikin (KAR) receptor KAI2. KK181N1 binds to the catalytic pockets of KAI2 in a non-covalent binding manner. KK181N1 selectively depress the KAR-induced phenotypes in Arabidopsis .
    KK181N1
  • HY-100520

    EGFR Cancer
    EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor.
    EGFR-IN-2
  • HY-101790

    NEDD8-activating Enzyme Cancer
    ZM223 is a potent non-covalent NEDD8 activating enzyme (NAE) inhibitor, orally active .
    ZM223
  • HY-P10118A

    Cathepsin Others
    Cathepsin L-IN-3 (Compound cat L inh. 7) TFA is selective a noncovalent cathepsin L inhibitor with a Ki of 4.3 nM .
    Cathepsin L-IN-3 TFA
  • HY-147036

    Orthopoxvirus Infection
    TTP-6171 is a non-covalent inhibitor of Monkeypox virus I7L protease, and it can be used for research on poxvirus infections .
    TTP-6171
  • HY-P10188

    Apolipoprotein Cardiovascular Disease
    apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity .
    apoB (4372-4392)
  • HY-W1048669B

    Biochemical Assay Reagents Others
    Biotin-PEG10000-DMG is a compound composed of biotin, PEG, and myristoyl-sn-glycerol, used for drug delivery. Biotin forms a stable non-covalent bond with streptavidin.
    Biotin-PEG10000-DMG
  • HY-W094751

    1-Pyrenamine (purified by sublimation)

    Biochemical Assay Reagents Others
    1-Pyrenamin (1-Pyrenamine purified by sublimation) is utilized to create highly efficient and stable catalyst supports in direct methanol fuel cells through noncovalent functionalization of graphite nanosheets .
    1-Pyrenamin
  • HY-123531

    Cathepsin Inflammation/Immunology
    JNJ 10329670 is a potent and selective noncovalent cathepsin S inhibitor with a Ki value of 34 nM for human cathepsin S. JNJ 10329670 blocks invariant chain proteolysis in B cells and dendritic cells, as well as antigen-induced T cell proliferation .
    JNJ 10329670

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: